Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (41394)	6/8/2014 8:51:09 AM
From: Pogeu Mahone	Respond to of 52153

Peter LOL "Peter (arguing the pro-D side here!)" You are not and never will be arguing the pro side as you have stated over and over you need controlled trials which you will never get in your lifetime. Mass General stated in May 2013, D3 is totally ineffective for Rheumatoid arthritis at a very high dose of 8000 iu! I could have told them that before they started that waste of time D3 study. Every health professional disbelieves this study from the 1930s, why? This article has saved mine and my families quality of life. vitamindcouncil.org A friend put his 9 year old 140 lb pit bull with bad hips on 50,000 iu and six weeks later the dogs is active again. He had been giving him glucosamine and chondroitin which is expensive and did not afford any relief to the puppy. My wife`s choice 100,000 D3 or listen to an expert who would dose her with this! Spinal Stenosis MedicationAuthor: John K Hsiang, MD, PhD; more... Overview Presentation DDx Workup Treatment Medication Updated: Mar 26, 2014 Medication Summary Nonsteroidal Anti-inflammatory Drugs Analgesics Muscle Relaxants Anticonvulsants Antidepressant, Tricyclic Corticosteroids Show All Multimedia Library References Medication Summary First-line pharmacotherapy for lumbar spinal stenosis (LSS) includes nonsteroidal anti-inflammatory drugs (NSAIDs), which provide analgesia at low doses and quell inflammation at high doses. An appropriate therapeutic NSAID plasma level is required to achieve anti-inflammatory benefit. NSAIDs retain a dose-related analgesic ceiling point, above which larger doses do not confer further pain control. Aspirin, which binds irreversibly to cyclo-oxygenase and requires larger doses to control inflammation, may cause gastritis; consequently, it is not recommended. Additionally, it may induce multiorgan toxicity, including renal insufficiency, peptic ulcer disease, and hepatic dysfunction. Cyclo-oxygenase (COX) isomer type 2 (COX-2) NSAID inhibitors reduce such toxicity. Tramadol and acetaminophen confer analgesia but do not affect inflammation. Muscle relaxants may be used to potentiate NSAID analgesia. Sedation results from muscle relaxation, promoting further patient relaxation. Such sedative side effects encourage evening dosing for patients who need to get sufficient sleep but may limit safe performance of some functional activities. Membrane-stabilizing anticonvulsants, such as gabapentin and carbamazepine, may reduce neuropathic radicular pain from lateral recess stenosis. These agents have central and peripheral anticholinergic effects, as well as sedative effects, and block the active reuptake of norepinephrine and serotonin. The multifactorial mechanism of analgesia could include improved sleep, altered perception of pain, and increase in pain threshold. Rarely should these drugs be used in treatment of acute pain, since a few weeks may be required for them to become effective. Tricyclic antidepressants (TCAs) are often given for neuropathic pain, but their adverse effects limit their use in elderly persons. These include somnolence, dry mouth, dry eyes, and constipation. More concerning are the possible arrhythmias that may occur when used in combination with other medications. Oral opioids may be prescribed on a scheduled short-term basis. Consequently, co-treatment with a psychologist or other addiction specialist is recommended for patients with a history of substance abuse. Patients may be asked to sign a medication contract restricting them to 1 practitioner, 1 pharmacy, scheduled medication use, no unscheduled refills, and no sharing or selling of medication.